ARTICLES BY THIS AUTHOR
- 4/4/2013
Walking the fine line of self-disclosure
While boundary violation fears are legitimate, bringing up your experiences can also spark a connection and empathy - 4/4/2013
ICU registered nurses at Kingston General Hospital call for independent review
Concerned about patient safety and staffing levels - 4/4/2013
Press Review - April 5, 2013
Check out our review of recent medical stories in the media - <strong>Top Story: </strong>Personalized prescriptions reduce side effects, increase efficiency. Read this and - 4/4/2013
Why putting training on pause should be an option
Rather than derailing your career, time off may actually make you a better doctor - 4/4/2013
History’s lost ‘heroic’ helper
For centuries, heroin was an effective pain reliever, easing difficult labours for many women - 4/4/2013
Edarbi and Edarbyclor for hypertension
Takeda Canada is introducing a new angiotensin II blocker (ARB) for the treatment of hypertension. - 4/4/2013
Reader Response: When did dispensing become a dirty word?
How can we expect others to respect what we do when we act like we need to re-invent ourselves? - 4/4/2013
Practice expenses tax auditors love to challenge
Home offices, vehicle costs and travel expenses are just some of the areas requiring extra care - 4/4/2013
Cancer group, drug company pan Quebec decision on prostate cancer treatment
OTTAWA and MONTREAL | The Canadian Cancer Survivor Network has expressed disappointment that Quebec's Institut national d'excellence en santé et en services sociaux (INESSS) did not recommend cabazitaxel, a chemotherapy shown to have a significant survival benefit for men with metastatic hormone-refractory prostate cancer who are not responding to other treatments.